Docosahexaenoic Acid and Preterm Birth
- PMID: 27842314
- DOI: 10.1159/000448263
Docosahexaenoic Acid and Preterm Birth
Abstract
Preterm birth accounts for more than 85% of all perinatal complications and deaths. There are many short- and long-term consequences of being born too soon. These infants often require intensive care and are at increased risk of early morbidities often with life-long sequelae. Approximately 50% of all preterm births have unknown or unclear causes, and there are no effective primary prevention strategies in widespread clinical use. Epidemiological studies have observed an increased length of gestation in populations with high fish consumption. These findings have led to randomised controlled trials of omega-3 (n-3) long-chain polyunsaturated fatty acid (LCPUFA) supplementation which show that these dietary agents may delay the timing of birth and may have value as a prophylactic intervention in some women. This review presents the available evidence and discusses the relationship between prenatal n-3 LCPUFA supplementation during pregnancy and the incidence of preterm birth.
© 2016 S. Karger AG, Basel.
Similar articles
-
Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial.BMJ Open. 2017 Sep 24;7(9):e018360. doi: 10.1136/bmjopen-2017-018360. BMJ Open. 2017. PMID: 28947468 Free PMC article. Clinical Trial.
-
ISSFAL statement number 7 - Omega-3 fatty acids during pregnancy to reduce preterm birth.Prostaglandins Leukot Essent Fatty Acids. 2022 Nov;186:102495. doi: 10.1016/j.plefa.2022.102495. Epub 2022 Sep 30. Prostaglandins Leukot Essent Fatty Acids. 2022. PMID: 36228573 Review.
-
A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery.N Engl J Med. 2019 Sep 12;381(11):1035-1045. doi: 10.1056/NEJMoa1816832. N Engl J Med. 2019. PMID: 31509674 Clinical Trial.
-
Omega-3 fatty acid supplementation in pregnancy-baseline omega-3 status and early preterm birth: exploratory analysis of a randomised controlled trial.BJOG. 2020 Jul;127(8):975-981. doi: 10.1111/1471-0528.16168. Epub 2020 Mar 3. BJOG. 2020. PMID: 32034969
-
Omega-3 fatty acid supply in pregnancy for risk reduction of preterm and early preterm birth.Am J Obstet Gynecol MFM. 2024 Feb;6(2):101251. doi: 10.1016/j.ajogmf.2023.101251. Epub 2023 Dec 7. Am J Obstet Gynecol MFM. 2024. PMID: 38070679 Review.
Cited by
-
Omega-3 Fatty Acids and Fecundation, Pregnancy and Breastfeeding.Rev Bras Ginecol Obstet. 2020 Mar;42(3):160-164. doi: 10.1055/s-0040-1708090. Epub 2020 Mar 31. Rev Bras Ginecol Obstet. 2020. PMID: 32232824 Free PMC article. Review.
-
Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)-Should They Be Mandatory Supplements in Pregnancy?Biomedicines. 2024 Jul 3;12(7):1471. doi: 10.3390/biomedicines12071471. Biomedicines. 2024. PMID: 39062044 Free PMC article. Review.
-
Omega-3 polyunsaturated fatty acid intake norms and preterm birth rate: a cross-sectional analysis of 184 countries.BMJ Open. 2019 Apr 20;9(4):e027249. doi: 10.1136/bmjopen-2018-027249. BMJ Open. 2019. PMID: 31005937 Free PMC article.
-
Prenatal Maternal Docosahexaenoic Acid (DHA) Supplementation and Newborn Anthropometry in India: Findings from DHANI.Nutrients. 2021 Feb 25;13(3):730. doi: 10.3390/nu13030730. Nutrients. 2021. PMID: 33668849 Free PMC article. Clinical Trial.
-
Does Omega-3 supplementation increase profuse postpartum hemorrhage? A hospital-based register study.Acta Obstet Gynecol Scand. 2024 Dec;103(12):2532-2539. doi: 10.1111/aogs.14987. Epub 2024 Oct 20. Acta Obstet Gynecol Scand. 2024. PMID: 39427322 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical